Cancer and the dopamine D2 receptor: a pharmacological perspective.

Cancer and the dopamine D2 receptor: a pharmacological perspective.
Related ArticlesCancer and the dopamine D2 receptor: a pharmacological perspective. J Pharmacol Exp Ther. 2019 Apr 18;: Authors: Weissenrieder JS, Neighbors JD, Mailman RB, Hohl RJ Abstract The dopamine D2 receptor (D2R) family is upregulated in many cancers, and tied to stemness, while cancer risk may correlate with dopamine-related disorders such as schizophrenia and Parkinson's disease. D2R antagonists also have ... read more
Source: PubMedPublished on 2019-04-20